Breakthrough in Anti-Aging Research: 20-Year Study Reveals Promising Compounds
The first comprehensive review of the National Institute on Aging’s Interventions Testing Program (ITP) has been published, highlighting 13 interventions that show promise in extending lifespan and improving healthspan. The study, which analyzed two decades of research, identified rapamycin as the most effective compound in promoting longevity.
Aging is a major risk factor for most chronic diseases, including cancer, cardiovascular disease, neurodegenerative disease, and metabolic disorders. Extending healthspan, or the period of life spent without serious disabilities or disease, is a central goal of modern aging research. The ITP was established in 2004 to test orally deliverable compounds that have the potential to delay aging and extend healthspan.
Genesis of the Interventions Testing Program
The National Institute on Aging was established in 1974, with a dual focus on the biology of aging and Alzheimer’s disease and related dementias. The ITP was launched to propose a different approach to research, testing compounds that have the potential to influence longevity. The Sam and Ann Barshop Institute for Longevity and Aging Studies was selected, along with two other sites, to conduct these studies.
James F. Nelson, PhD, professor in the Department of Cellular and Integrative Physiology and the Barshop Institute at The University of Texas Health Science Center at San Antonio, has participated in the ITP from the beginning. He notes that the program’s findings could redefine how scientists understand the biology of aging and our potential to change its trajectory.
Breakthrough of Rapamycin
A landmark publication in the July 2025 issue of the Journal of Gerontology: Biological Science, is the first comprehensive review of the ITP’s discoveries using genetically heterogeneous mice. The review found that rapamycin is the most effective compound tested through the ITP so far, extending the lifespan of animal models by up to 28%, even when delivered in middle age or later in life.
Rapamycin was first discovered in the 1960s and was found to suppress the mTOR pathway, thereby shunting energy from growth to maintenance. The compound has been highlighted as a potential longevity drug by the ITP, and its effects on aging are being further investigated.
Looking Ahead
All the ITP’s studies are published, and the data are freely available, encouraging further investigation and validation of compounds by the broader scientific community. The surge in interest surrounding longevity and aging research in recent years is evident, with the ITP receiving more than 28 annual proposals in the past three years, up from an average of four.
As research in this field continues to advance, it is likely that new breakthroughs will be made, and our understanding of the biology of aging will be further refined. For more information on this study and the Interventions Testing Program, visit Here
Image Credit: news.uthscsa.edu